Retatrutide, the new dual GLP-1 and GIP receptor agonist, is initially not widely available in the British Isles . While studies are ongoing, formal launch dates remain unspecified . Patients interested https://elodiepszz230775.pointblog.net/the-retatrutide-a-guide-to-access-information-93849373